KRAS G13D-IN-1
KRAS G13D-IN-1 (Compound 41) is a selective and covalently reversible inhibitor of KRASG13D (IC50: 0.41 nM). The selectivity for KRASG13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRASG13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades. KRAS G13D-IN-1 can be used in the research of colon cancer.
For research use only. We do not sell to patients.
- Formula: C43H45ClF4N8O2
- Molecular Weight:817.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
KRAS G13D 0.41 nM (IC50) |
In Vitro
Chemical Information
-
Molecular Weight 817.32
-
Formula C43H45ClF4N8O2
-
SMILES
NC1=N[C@@]([C@@]2=C(F)C3=C(C(N4[C@@H](C)CN(C(/C=C/C5=CC=CC6=C5C[N@@]7C[C@H]6CC7)=O)CC4)=NC(OC[C@@]89CCCN8CC(C9)=C)=N3)C=C2Cl)=C(C(F)(F)F)C(C)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)